APS Stock Overview
A biotech company, researches and develops pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Asarina Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.004 |
| 52 Week High | SEK 0.096 |
| 52 Week Low | SEK 0.0002 |
| Beta | 0.17 |
| 11 Month Change | -35.48% |
| 3 Month Change | -91.15% |
| 1 Year Change | -93.49% |
| 33 Year Change | -98.44% |
| 5 Year Change | n/a |
| Change since IPO | -99.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| APS | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1,900.0% | 3.1% | 4.5% |
| 1Y | -93.5% | -12.1% | 13.4% |
Return vs Industry: APS underperformed the German Pharmaceuticals industry which returned -12.6% over the past year.
Return vs Market: APS underperformed the German Market which returned 12.6% over the past year.
Price Volatility
| APS volatility | |
|---|---|
| APS Average Weekly Movement | 3,141.5% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: APS's share price has been volatile over the past 3 months.
Volatility Over Time: APS's weekly volatility has increased from 1694% to 3142% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 6 | Peter Nordkild | www.asarinapharma.com |
Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products. Its’s product is Sepranolone, which is used for the treatment of allopregnanolone-induced stress- and compulsivity-driven disorders from Tourette syndrome to Obsessivecompulsive disorder syndrome. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016.
Asarina Pharma AB (publ) Fundamentals Summary
| APS fundamental statistics | |
|---|---|
| Market cap | €96.39k |
| Earnings (TTM) | -€1.14m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs APS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APS income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 12.83m |
| Earnings | -SEK 12.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 60.6% |
How did APS perform over the long term?
See historical performance and comparison